

PHARMANUTRA S.P.A.: 2025 SUSTAINABILITY REPORT RELEASED

Pisa, 13 July 2026 – [Pharmanutra](#) (MTA; Ticker PHN), a company specialising in mineral-based nutritional supplements and medical devices for muscles and joints, today published its **2025 Sustainability Report**, compiled in accordance with GRI (Global Reporting Initiative) standards, pursuant to the “*in accordance*” approach.

The 2025 Sustainability Report was drawn up on a voluntary basis, as the Company is exempt from the mandatory requirement to report a Sustainability Statement under Legislative Decree 125/2024 currently in force, and is subject to a limited review.

The Group undertook several ESG initiatives during 2025, notably those relating to the environment, including the start of the procedure for obtaining ISO 14001 certification and the signing of contracts for the supply of energy from renewable sources.

The Group has also focused on improving its reporting on Scope 3 emissions by launching, in collaboration with the Department of Energy, Systems, Land, and Construction Engineering at the University of Pisa, a **pilot Life Cycle Assessment** (LCA) project, which involves an environmental impact analysis applied to the main upstream stages of the SiderAL® r.m. value chain - one of the strategic raw materials for various Group finished products, including SiderAL® Forte.

The Pharmanutra Group recognizes the importance of sustainable development and translates this commitment into its connection with the community and the local area, as well as into respect for the environment and the people involved.

The full document is available at the following link: pharmanutragroup.com/en/sustainability/esg-plan

Pharmanutra S.p.A.

Via Campodavola, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259



Pharmanutra S.p.A.

Founded in 2003 in Pisa by Andrea and Roberto Lacorte, Pharmanutra is the holding company of an international Group engaged in the research, development, and commercialization of nutritional supplements, medical devices, and patented raw materials. A leader in iron-based supplements through its Sucrosomial® Technology (SiderAL® and Apportal®), and an emerging player in medical devices for mobility (Cetilar®), the Group internally manages the entire value chain and holds a solid portfolio of patents, brands, and clinical evidence.

Pharmanutra operates in over 80 countries, with subsidiaries in the USA and Spain, and also includes Akern S.r.l. (bioimpedance analysis) and Athletica Cetilar S.r.l. (sports medicine)

pharmanutragroup.com

pharmanutra.it

For further information:

Pharmanutra S.p.A.

Via Campodavella 1 - 56122 Pisa

Tel. +39 050 7846500

Simona Del Re

s.delre@pharmanutra.it

investorrelation@pharmanutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milano

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Pharmanutra S.p.A.

Via Campodavella, 1 - 56122 Pisa | +39 050 7846500

pharmanutragroup.com | pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it

C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259

